个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

BIOMARKER ANALYSIS OF A RANDOMIZED, CONTROLLED, MULTICENTER CLINICAL TRIAL COMPARING PEMETREXED/CISPLATIN AND GMCITABINE/CISPLATIN AS FIRST-LINE TREATMENT FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER

| 导出 |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE

作者：
Zhang, Li[1] * ; Huang, Yan[1] ; Hu, Zhihuang[1] ; Liu, Yun-Peng[2,24] ; Zhou, Jianying[3,25] ; Xu, Nong[4,26] ; Li, Baolan[5,27] ; Wu, Gang[6,28] ; Liu, Xiaoqing[7,29] ; Fang, Jian[8,30] ; Li, Kai[9,31] ; Wei, Liu[10,32] ; Lu, You[11,33] ; Wang, Meng-Zhao[12,34] ; Liu, Wenzhao[13,35] ; Liang, Houjie[14,36] ; Zhang, Yiping[15,37] ; Huang, Cheng[16,38] ; Wang, Shunjin[17,39] ; Wang, Yajie[18,40] ; Yu, Shiying[19,41] ; Chang, Jianhua[20,42] ; Wang, Zhehai[21,22,23,43] ;
机构： [1]Sun Yat Sen Univ, Ctr Canc, Guangzhou, Guangdong, Peoples R China [2]China Med Univ, Hosp 1, Dept Med Oncol, Shenyang, Liaoning, Peoples R China [3]Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Resp Dis, Hangzhou, Zhejiang, Peoples R China [4]Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Chemotherapy, Hangzhou, Zhejiang, Peoples R China [5]Capital Med Hosp, Beijing Chest Hosp, Dept Gen Med, Beijing, Peoples R China [6]Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Tumor Ctr, Wuhan, Hubei, Peoples R China [7]Acad Mil Med Sci, Affiliated Hosp, Dept Thorac Med Oncol, Beijing, Peoples R China [8]Beijing Canc Hosp & Inst, Dept Thorac Med Oncol, Beijing, Peoples R China [9]Tianjin Med Univ Canc Inst & Hosp, Dept Thorac Med Oncol, Tianjin, Peoples R China [10]Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China [11]Sichuan Univ, West China Sch Med, West China Hosp, Dept Thorac Oncol, Chengdu, Sichuan, Peoples R China [12]Beijing Union Med Coll Hosp, Dept Resp Dis, Beijing, Peoples R China [13]Fourth Mil Med Univ, Xijing Hosp, Dept Oncol, Xian, Peoples R China [14]Third Mil Med Univ, Affiliated Hosp 1, Dept Oncol, Chongqing, Peoples R China [15]Zhejiang Canc Hosp, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China [16]Fujian Prov Canc Hosp, Dept Thorac Oncol, Fuzhou, Fujian, Peoples R China [17]Nanchang Univ, Affiliated Hosp 2, Dept Oncol, Nanchang, Peoples R China [18]Shanghai Second Mil Med Univ, Changhai Hosp, Dept Oncol, Shanghai, Peoples R China [19]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Caner Ctr, Wuhan, Hubei, Peoples R China [20]Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai, Peoples R China [21]Shandong Canc Hosp, Dept Med Oncol, Jinan, Peoples R China [Zhang, Li[22]Huang, Yan [23]Hu, Zhihuang] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Guangdong, Peoples R China [24]China Med Univ, Hosp 1, Dept Med Oncol, Shenyang, Liaoning, Peoples R China [25]Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Resp Dis, Hangzhou, Zhejiang, Peoples R China [26]Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Chemotherapy, Hangzhou, Zhejiang, Peoples R China [27]Capital Med Hosp, Beijing Chest Hosp, Dept Gen Med, Beijing, Peoples R China [28]Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Tumor Ctr, Wuhan, Hubei, Peoples R China [29]Acad Mil Med Sci, Affiliated Hosp, Dept Thorac Med Oncol, Beijing, Peoples R China [30]Beijing Canc Hosp & Inst, Dept Thorac Med Oncol, Beijing, Peoples R China [31]Tianjin Med Univ Canc Inst & Hosp, Dept Thorac Med Oncol, Tianjin, Peoples R China [32]Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China [33]Sichuan Univ, West China Sch Med, West China Hosp, Dept Thorac Oncol, Chengdu, Sichuan, Peoples R China [34]Beijing Union Med Coll Hosp, Dept Resp Dis, Beijing, Peoples R China [35]Fourth Mil Med Univ, Xijing Hosp, Dept Oncol, Xian, Peoples R China [36]Third Mil Med Univ, Affiliated Hosp 1, Dept Oncol, Chongqing, Peoples R China [37]Zhejiang Canc Hosp, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China [38]Fujian Prov Canc Hosp, Dept Thorac Oncol, Fuzhou, Fujian, Peoples R China [39]Nanchang Univ, Affiliated Hosp 2, Dept Oncol, Nanchang, Peoples R China [40]Shanghai Second Mil Med Univ, Changhai Hosp, Dept Oncol, Shanghai, Peoples R China [41]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Caner Ctr, Wuhan, Hubei, Peoples R China [42]Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai, Peoples R China [43]Shandong Canc Hosp, Dept Med Oncol, Jinan, Peoples R China
出处：
ISSN：

关键词： Lung cancer chemotherapy biomarker

语种：
外文
WOS：
中科院分区：
出版当年[2013]版：
大类 | 2 区 医学
小类 | 2 区 呼吸系统 3 区 肿瘤学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
JCR分区：
出版当年[2013]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM
最新[2023]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 最新[2023版] 最新五年平均 出版当年[2013版] 出版当年五年平均 出版前一年[2012版] 出版后一年[2014版]

第一作者：
第一作者机构： [1]Sun Yat Sen Univ, Ctr Canc, Guangzhou, Guangdong, Peoples R China
推荐引用方式(GB/T 7714)：
Zhang Li,Huang Yan,Hu Zhihuang,et al.BIOMARKER ANALYSIS OF A RANDOMIZED, CONTROLLED, MULTICENTER CLINICAL TRIAL COMPARING PEMETREXED/CISPLATIN AND GMCITABINE/CISPLATIN AS FIRST-LINE TREATMENT FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER[J].JOURNAL OF THORACIC ONCOLOGY.2013,8:S330-S330.
APA：
Zhang, Li,Huang, Yan,Hu, Zhihuang,Liu, Yun-Peng,Zhou, Jianying...&Wang, Zhehai.(2013).BIOMARKER ANALYSIS OF A RANDOMIZED, CONTROLLED, MULTICENTER CLINICAL TRIAL COMPARING PEMETREXED/CISPLATIN AND GMCITABINE/CISPLATIN AS FIRST-LINE TREATMENT FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER.JOURNAL OF THORACIC ONCOLOGY,8,
MLA：
Zhang, Li,et al."BIOMARKER ANALYSIS OF A RANDOMIZED, CONTROLLED, MULTICENTER CLINICAL TRIAL COMPARING PEMETREXED/CISPLATIN AND GMCITABINE/CISPLATIN AS FIRST-LINE TREATMENT FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER".JOURNAL OF THORACIC ONCOLOGY 8.(2013):S330-S330

相关文献

[1]Bifidobacterium breve predicts the efficacy of anti-PD-1 immunotherapy combined with chemotherapy in Chinese NSCLC patients [2]P4HA1, a Prognostic Biomarker that Correlates With Immune Infiltrates in Lung Adenocarcinoma and Pan-Cancer. [3]Biomarker Exploration for neoadjuvant chemotherapy with gemcitabine combined with cisplatin in muscle-invasive bladder cancer [4]LncRNA-ATB Can Be a Biomarker for Diagnosis and Prognosis Evaluation of Non-Small Cell Lung Cancer [5]Circulating Tumor Cells as a Biomarker to Assist Molecular Diagnosis for Early Stage Non-Small Cell Lung Cancer [6]Recombinant human endostatin combined with chemotherapy for advanced squamous cell lung cancer: a meta-analysis. [7]SWI/SNF complex signature as a novel biomarker for immunotherapy in patients with non-small cell lung cancer [8]First-line apatinib plus chemotherapy in extensive-stage small-cell lung cancer [9]Plasma ctDNA biomarker study in patients with non-small cell lung cancer with EGFR exon 20 insertion mutation treated with sunvozertinib [10]Plasma metabolomics study in screening and differential diagnosis of multiple primary lung cancer

资源点击量：39770 今日访问量：0 总访问量：1333 更新日期：2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持：重庆聚合科技有限公司 地址：河北省石家庄市健康路12号